Potential role of N-myristoyltransferase in cancer

Progress in Lipid Research

Volumn 46, Issue 1, 2007, Pages 1-36

  Selvakumar, Ponniah ^a   Lakshmikuttyamma, Ashakumary ^a   Shrivastav, Anuraag ^a   Das, Shankar B ^a   Dimmock, Jonathan R ^b   Sharma, Rajendra K ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cancer; Heat shock cognate protein 70; Inhibitors; Lipid modification; Myristoylation; Myristoyltransferase

Indexed keywords

PROTEIN N MYRISTOYLTRANSFERASE;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENESIS; COLORECTAL CARCINOMA; ENZYME ACTIVITY; GALLBLADDER CARCINOMA; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ACYLTRANSFERASES; BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; ENZYME INHIBITORS; GALLBLADDER NEOPLASMS; HUMANS; LIPID METABOLISM; MODELS, MOLECULAR; NEOPLASMS; PHOSPHORYLATION; TUMOR MARKERS, BIOLOGICAL;

EID: 33751298031     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plipres.2006.05.002     Document Type: Review

References (286)

1. Boring C.C., Squires T.S., Tong T., and Montgomery S. Cancer statistics 1994. CA Cancer J Clin 44 (1994) 7-26
2. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
3. Potter J.D. Colorectal cancer: molecules and populations. J Natl Cancer Inst 91 (1999) 916-932
4. Houlston R.S. What we could do now: molecular pathology of colorectal cancer. J Clin Pathol Mol Pathol 54 (2001) 206-214
5. Midgley R., and Kerr D. Conventional catatonic and novel therapeutic concepts in colorectal cancer. Expert Opin Invest Drugs 10 (2001) 1011-1019
6. Vetting M.W., de Carvalho L.P.S., Yu M., Hegde S.S., Magnet S., Roderick S.L., et al. Structure and functions of the GNAT superfamily of acetyltransferases. Arch Biochem Biophys 433 (2005) 212-226
7. Selvakumar P., Lakshmikuttyamma A., Shrivastav A., Dimmock J.R., and Sharma R.K. Myristoylation and cell signalling: involvement of heat shock protein 70 family. Recent Dev Life Sci 3 (2005) 75-82
8. Shrivastav A., Selvakumar P., Bajaj G., Lu Y., Dimmock J.R., and Sharma R.K. Regulation of N-myristoyltransferase by novel inhibitor proteins. Cell Biochem Biophys 43 (2005) 189-202
9. Selvakumar P., Pasha M.K., Ashakumary L., Dimmock J.R., and Sharma R.K. Myristoyl-CoA: protein N-myristoyltransferase: a novel molecular approach for cancer therapy. Int J Mol Med 10 (2002) 493-500
10. Farazi T.A., Waksman G., and Gordon J.I. The biology and enzymology of protein N-myristoylation. J Biol Chem 276 (2001) 39501-39504
11. Resh M.D. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim. Biophys Acta 1451 (1999) 1-16
12. Boutin J.A. Myristoylation. Cell Signal 9 (1997) 15-35
13. Raju R.V., Magnuson B.A., and Sharma R.K. Mammalian myristoyl CoA: protein NMT. Mol Cell Biochem 149/150 (1995) 191-202
14. Casey P.J. Protein lipidation in cell signaling. Science 268 (1995) 221-225
15. Selvakumar P., Lakshmikuttyamma A., Dimmock J.R., and Sharma R.K. Methionine aminopeptidase 2 and cancer. Biochim Biophys Acta - Reviews in Cancer 1765 (2006) 148-154
16. 2-terminal blocking group of the catalytic subunit of cyclic AMP dependent protein kinase from bovine cardiac muscle. Proc Natl Acad Sci USA 79 (1982) 6128-6131
17. Zha J., Weiler S., Oh K.J., Wei M.C., and Korsmeyer S.J. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 290 (2000) 1761-1765
18. Besse S., Rebouillat D., Marie I., Puvion-Dutilleul F., and Hovanessian A.G. Ultrastructural localization of interferon-inducible double-stranded RNA-activated enzymes in human cells. Exp Cell Res 239 (1998) 379-392
19. Maurer-Stroh S., Eisenhaber B., and Eisenhaber F. N-terminal N-myristoylation of proteins: prediction of substrate proteins from amino acid sequence. J Mol Biol 317 (2002) 541-557
20. Kimura Y., Saeki Y., Yokosawa H., Polevoda B., Sherman F., and Hirano H. N-terminal modifications of the 19S regulatory particle subunits of the yeast proteasome. Arch Biochem Biophys 409 (2003) 341-348
21. Brooks P., Fuertes G., Murray R.Z., Bose S., Knecht E., Rechsteiner M.C., et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 346 (2000) 155-161
22. Marchand S., Devillers-Thiery A., Pons S., Changeux J.P., and Cartaud J. Rapsyn escorts the nicotinic acetylcholine receptor along the exocytic pathway via association with lipid rafts. J Neurosci 22 (2002) 8891-8901
23. Hunter C., Sung P., Schejter E.D., and Wieschaus E. Conserved domains of the Nullo protein required for cell-surface localization and formation of adherens junctions. Mol Biol Cell 13 (2002) 146-157
24. Collavin L., Lazarevic D., Utrera R., Marzinotto S., Monte M., and Schneider C. WT p53 dependent expression of a membrane-associated isoform of adenylate kinase. Oncogene 18 (1999) 5879-5888
25. Randazzo P.A., Nie Z., Miura K., and Hsu V.W. Molecular aspects of the cellular activities of ADP-ribosylation factors. Sci STKE 2000 (2000) RE1
26. Lin C.Y., Li C.C., Huang P.H., and Lee F.J. A developmentally regulated ARF-like 5 protein (ARL5), localized to nuclei and nucleoli, interacts with heterochromatin protein 1. J Cell Sci 115 (2002) 4433-4445
27. Rossi E.A., Li Z., Feng H., and Rubin C.S. Characterization of the targeting, binding, and phosphorylation site domains of an A kinase anchor protein and a myristoylated alanine-rich C kinase substrate-like analog that are encoded by a single gene. J Biol Chem 274 (1999) 27201-27210
28. Fraser I.D., Tavalin S.J., Lester L.B., Langeberg L.K., Westphal A.M., Dean R.A., et al. A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. EMBO J 17 (1998) 2261-2272
29. Lafont F., Lecat S., Verkade P., and Simons K. Annexin XIIIb associates with lipid microdomains to function in apical delivery. J Cell Biol 142 (1998) 1413-1427
30. Lu S.X., and Hrabak E.M. An Arabidopsis calcium-dependent protein kinase is associated with the endoplasmic reticulum. Plant Physiol 128 (2002) 1008-1021
31. 2+- and myristoylation-dependent association of calcineurin with phosphatidylserine. J Biochem 129 (2001) 835-841
32. 2+-binding protein p22 associates with microtubules in an N-myristoylation-dependent manner. Mol Biol Cell 10 (1999) 3473-3488
33. Li S., and Goldberg E. A novel N-terminal domain directs membrane localization of mouse testis-specific calpastatin. Biol Reprod 63 (2000) 1594-1600
34. Pepperkok R., Hotz-Wagenblatt A., Konig N., Girod A., Bossemeyer D., and Kinzel V. Intracellular distribution of mammalian protein kinase A catalytic subunit altered by conserved Asn2 deamidation. J Cell Biol 148 (2000) 715-726
35. Vaandrager A.B., Smolenski A., Tilly B.C., Houtsmuller A.B., Ehlert E.M., Bot A.G., et al. Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl-channel activation. Proc Natl Acad Sci USA 95 (1998) 1466-1471
36. Stabler S.M., Ostrowski L.L., Janicki S.M., and Monteiro M.J. A myristoylated calcium-binding protein that preferentially interacts with the Alzheimer's disease presenilin 2 protein. J Cell Biol 145 (1999) 1277-1292
37. Naik U.P., and Naik M.U. Association of CIB with GPIIb/IIIa during outside-in signaling is required for platelet spreading on fibrinogen. Blood 102 (2003) 1355-1362
38. Liu J., Hughes T.E., and Sessa W.C. The first 35 amino acids and fatty acylation sites determine the molecular targeting of endothelial nitric oxide synthase into the Golgi region of cells: a green fluorescent protein study. J Cell Biol 137 (1997) 1525-1535
39. Michel T. Targeting and translocation of endothelial nitric oxide synthase. Braz J Med Biol Res 32 (1999) 1361-1366
40. Risinger M.A., Korsgren C., and Cohen C.M. Role of N-myristoylation in targeting of band 4.2 (pallidin) in nonerythroid cells. Exp Cell Res 229 (1996) 421-431
41. Sullivan A., Uff C.R., Isacke C.M., and Thorne R.F. PACE-1, a novel protein that interacts with the C-terminal domain of ezrin. Exp Cell Res 284 (2003) 224-238
42. Martin G.B., Bogdanove A.J., and Sessa G. Understanding the functions of plant disease resistance proteins. Annu Rev Plant Biol 54 (2003) 23-61
43. Godsel L.M., and Engman D.M. Flagellar protein localization mediated by a calcium-myristoyl/palmitoyl switch mechanism. EMBO J 18 (1999) 2057-2065
44. Quest A.F., Harvey D.J., and McIlhinney R.A. Myristoylated and nonmyristoylated pools of sea urchin sperm flagellar creatine kinase exist side-by-side: myristoylation is necessary for efficient lipid association. Biochemistry 36 (1997) 6993-7002
45. Uno F., Sasaki J., Nishizaki M., Carboni G., Xu K., Atkinson E.N., et al. Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res. 64 (2004) 2969-2976
46. Kamata N., and Holt J.T. Inhibitory effect of myristoylation on transrepression by FBR (Gag-Fos) protein. Mol Cell Biol 12 (1992) 876-882
47. Rhee S.S., and Hunter E. Myristoylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol 61 (1987) 1045-1053
48. Henderson L.E., Krutzsch H.C., and Oroszlan S. Myristoyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational proteins modification. Proc Natl Acad Sci USA 80 (1983) 339-343
49. Copeland N.G., Jenkins N.A., Nexo B., Schultz A.M., Rein A., Mikkelsen T., et al. Poorly expressed endogenous ecotropic provirus of DBA/2 mice encodes a mutant Pr65gag protein that is not myristoylated. J Virol 62 (1988) 479-487
50. Elder J.H., Schnolzer M., Hasselkus-Light C.S., Henson M., Lerner D.A., Phillips T.R., et al. Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus. J Virol 67 (1993) 1869-1876
51. Goddard C., Aquino A., Glazer R.I., and Felsted R.L. Chemical characterization of p17gag from human immunodeficiency virus as an N-terminally myristoylated protein. Eur J Biochem 182 (1989) 323-326
52. Pal R., Reitz Jr. M.S., Tschachler E., Gallo R.C., Sarngadharan M.G., and Veronese F.D. Myristoylation of gag proteins of HIV-1 plays an important role in virus assembly. AIDS Res Hum Retroviruses 6 (1990) 721-730
53. Bryant M., and Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci USA 87 (1990) 523-527
54. Burnette B., Kahn R., Glover C.J., and Felsted R.L. Bacterial expression, purification, and in vitro N-myristoylation of HIV-1 p17gag. Protein Expr Purif 3 (1992) 395-402
55. Shoji S., Tashiro A., and Kubota Y. Anti-myristoylation of gag proteins in human T-cell leukemia and human immunodeficiency viruses with N-myristoyl glycinal diethylacetal. J Biochem 103 (1988) 747-749
56. Hayakawa T., Miyazaki T., Misumi Y., Kobayashi M., and Fujisawa Y. Myristoylation-dependent membrane targeting and release of the HTLV-I Gag precursor, Pr53gag, in yeast. Gene 119 (1992) 273-277
57. Ootsuyama Y., Shimotohno K., Miwa M., Oroszlan S., and Sugimura T. Myristoylation of gag protein in human T-cell leukemia virus type-I and type-II. Jpn J Cancer Res 76 (1985) 1132-1135
58. Rhee S.S., and Hunter E. Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol 64 (1990) 4383-4389
59. Schultz A.M., and Rein A. Unmyristoylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events. J Virol 63 (1989) 2370-2373
60. Hizi A., Henderson L.E., Copeland T.D., Sowder R.C., Krutzsch H.C., and Oroszlan S. Analysis of gag proteins from mouse mammary tumor virus. J Virol 63 (1989) 2543-2549
61. Huang M., and Jolicoeur P. Myristylation of Pr60gag of the murine AIDS-defective virus is required to induce disease and notably for the expansion of its target cells. J Virol 68 (1994) 5648-5655
62. Gonzalez S.A., Affranchino J.L., Gelderblom H.R., and Burny A. Assembly of the matrix protein of simian immunodeficiency virus into virus-like particles. Virology 194 (1993) 548-556
63. Harper D.R., Gilbert R.L., Blunt C., and McIlhinney R.A. Inhibition of varicella-zoster virus replication by an inhibitor of protein myristoylation. J Gen Virol 74 (1993) 1181-1184
64. Namazue J., Kato T., Okuno T., Shiraki K., and Yamanishi K. Evidence for attachment of fatty acid to varicella-zoster virus glycoproteins and effect of cerulenin on the maturation of varicella-zoster virus glycoproteins. Intervirology 30 (1989) 268-277
65. Barr F.A., Puype M., Vandekerckhove J., and Warren G. GRASP65, a protein involved in the stacking of Golgi cisternae. Cell 91 (1997) 253-262
66. Kuo A., Zhong C., Lane W.S., and Derynck R. Transmembrane transforming growth factor-alpha tethers to the PDZ domain-containing, Golgi membrane-associated protein p59/GRASP55. EMBO J 19 (2000) 6427-6439
67. Eberle H.B., Serrano R.L., Fullekrug J., Schlosser A., Lehmann W.D., Lottspeich F., et al. Identification and characterization of a novel human plant pathogenesis-related protein that localizes to lipid-enriched microdomains in the Golgi complex. J Cell Sci 115 (2002) 827-838
68. Chen C.A., and Manning D.R. Regulation of G proteins by covalent modification. Oncogene 20 (2001) 1643-1652
69. Moffett S., Brown D.A., and Linder M.E. Lipid-dependent targeting of G proteins into rafts. J Biol Chem 275 (2000) 2191-2198
70. Hwang J.Y., and Koch K.W. Calcium- and myristoyl-dependent properties of guanylate cyclase-activating protein-1 and protein-2. Biochemistry 41 (2002) 13021-13028
71. Hanakam F., Albrecht R., Eckerskorn C., Matzner M., and Gerisch G. Myristoylated and non-myristoylated forms of the pH sensor protein hisactophilin II: intracellular shuttling to plasma membrane and nucleus monitored in real time by a fusion with green fluorescent protein. EMBO J 15 (1996) 2935-2943
72. Denny P.W., Gokool S., Russell D.G., Field M.C., and Smith D.F. Acylation-dependent protein export in Leishmania. J Biol Chem 275 (2000) 11017-11025
73. Chung T.D., Wymer J.P., Kulka M., Smith C.C., and Aurelian L. Myristoylation and polylysine-mediated activation of the protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). Virology 179 (1990) 168-178
74. Neel V.A., and Young M.W. Igloo, a GAP-43-related gene expressed in the developing nervous system of Drosophila. Development 120 (1994) 2235-2243
75. Gripon P., Le Seyec J., Rumin S., and Guguen-Guillouzo C. Myristoylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213 (1995) 292-299
76. Ravanello M.P., and Hruby D.E. Conditional lethal expression of the vaccinia virus L1R myristoylated protein reveals a role in virion assembly. J Virol 68 (1994) 6401-6410
77. 2-terminal peptide from the vaccinia virus L1R protein directs the myristoylation and virion envelope localization of a heterologous fusion protein. J Biol Chem 268 (1993) 7585-7593
78. Franke C.A., Wilson E.M., and Hruby D.E. Use of a cell-free system to identify the vaccinia virus L1R gene product as the major late myristoylated virion protein M25. J Virol 64 (1990) 5988-5996
79. Weaver T.A., and Panganiban A.T. N myristoylation of the spleen necrosis virus matrix protein is required for correct association of the Gag polyprotein with intracellular membranes and for particle formation. J Virol 64 (1990) 3995-4001
80. Arbuzova A., Schmitz A.A., and Vergeres G. Cross-talk unfolded: MARCKS proteins. Biochem J 362 (2002) 1-12
81. Borgese N., Aggujaro D., Carrera P., Pietrini G., and Bassetti M. A role for N-myristoylation in protein targeting: NADH-cytochrome b5 reductase requires myristic acid for association with outer mitochondrial but not ER membranes. J Cell Biol 135 (1996) 1501-1513
82. Walker J.E., Arizmendi J.M., Dupuis A., Fearnley I.M., Finel M., Medd S.M., et al. Sequences of 20 subunits of NADH:ubiquinone oxidoreductase from bovine heart mitochondria. Application of a novel strategy for sequencing proteins using the polymerase chain reaction. J Mol Biol 226 (1992) 1051-1072
83. Jacobs E., Gheysen D., Thines D., Francotte M., and de Wilde M. The HIV-1 Gag precursor Pr55gag synthesized in yeast is myristoylated and targeted to the plasma membrane. Gene 79 (1989) 71-81
84. Terashita A., Funatsu N., Umeda M., Shimada Y., Ohno-Iwashita Y., Epand R.M., et al. Lipid binding activity of a neuron-specific protein NAP-22 studied in vivo and in vitro. J Neurosci Res 70 (2002) 172-179
85. Belsham G.J., Abrams C.C., King A.M., Roosien J., and Vlak J.M. Myristoylation of foot-and-mouth disease virus capsid protein precursors is independent of other viral proteins and occurs in both mammalian and insect cells. J Gen Virol 72 (1991) 747-751
86. Que Q., Li Y., Wang I.N., Lane L.C., Chaney W.G., and Van Etten J.L. Protein glycosylation and myristoylation in Chlorella virus PBCV-1 and its antigenic variants. Virology 203 (1994) 320-327
87. Furuya T., Kashuba C., Docampo R., and Moreno S.N. A novel phosphatidylinositol-phospholipase C of Trypanosoma cruzi that is lipid modified and activated during trypomastigote to amastigote differentiation. J Biol Chem 275 (2000) 6428-6438
88. Macrae D.R., Bruss V., and Ganem D. Myristoylation of a duck hepatitis B virus envelope protein is essential for infectivity but not for virus assembly. Virology 181 (1991) 359-363
89. Prange R., Clemen A., and Streeck R.E. Myristoylation is involved in intracellular retention of hepatitis B virus envelope proteins. J Virol 65 (1991) 3919-3923
90. Konno D., Ko J.A., Usui S., Hori K., Maruoka H., Inui M., et al. The postsynaptic density and dendritic raft localization of PSD-Zip70, which contains an N-myristoylation sequence and leucine-zipper motifs. J Cell Sci 115 (2002) 4695-4706
91. Ueda T., Yamaguchi M., Uchimiya H., and Nakano A. Ara6, a plant-unique novel type Rab GTPase, functions in the endocytic pathway of Arabidopsis thaliana. EMBO J 20 (2001) 4730-4741
92. 2+ signal transduction. J Biol Chem 277 (2002) 14227-14237
93. Spilker C., Dresbach T., and Braunewell K.H. Reversible translocation and activity-dependent localization of the calcium-myristoyl switch protein VILIP-1 to different membrane compartments in living hippocampal neurons. J Neurosci 22 (2002) 7331-7339
94. Lin S.S., Manchester J.K., and Gordon J.I. Sip2, an N-myristoylated beta subunit of Snf1 kinase, regulates aging in Saccharomyces cerevisiae by affecting cellular histone kinase activity, recombination at rDNA loci, and silencing. J Biol Chem 278 (2003) 13390-13397
95. Gelman I.H., Lee K., Tombler E., Gordon R., and Lin X. Control of cytoskeletal architecture by the src-suppressed C kinase substrate, SSeCKS. Cell Motil Cytoskeleton 41 (1998) 1-17
96. Utsumi T., Sakurai N., Nakano K., and Ishisaka R. C-terminal 15 kDa fragment of cytoskeletal actin is posttranslationally N-myristoylated upon caspase-mediated cleavage and targeted to mitochondria. FEBS Lett 539 (2003) 37-44
97. 2-terminal kinase activation. J Cell Biol 137 (1997) 387-398
98. Lang M.L., Chen Y.W., Shen L., Gao H., Lang G.A., Wade T.K., et al. IgA Fc receptor (FcalphaR) cross-linking recruits tyrosine kinases, phosphoinositide kinases and serine/threonine kinases to glycolipid rafts. Biochem J 364 (2002) 517-525
99. MacLean C.A., Clark B., and McGeoch D.J. Gene UL11 of herpes simplex virus type 1 encodes a virion protein which is myristoylated. J Gen Virol 70 (1989) 3147-3157
100. MacLean C.A., Dolan A., Jamieson F.E., and McGeoch D.J. The myristoylated virion proteins of herpes simplex virus type 1: investigation of their role in the virus life cycle. J Gen Virol 73 (1992) 539-547
101. Bellacosa A., Franke T.F., Gonzalez-Portal M.E., Datta K., Taguchi T., Gardner J., et al. Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogene 8 (1993) 745-754
102. Abbott D.W., and Holt J.T. Finkel-Biskis-Reilly mouse osteosarcoma virus v-fos inhibits the cellular response to ionizing radiation in a myristoylation-dependent manner. J Biol Chem 272 (1997) 14005-14008
103. Schmidt M., Muller H., Schmidt M.F., and Rott R. Myristoylation of budgerigar fledgling disease virus capsid protein VP2. J Virol 63 (1989) 429-431
104. Krauzewicz N., Streuli C.H., Stuart-Smith N., Jones M.D., Wallace S., and Griffin B.E. Myristoylated polyomavirus VP2: role in the life cycle of the virus. J Virol 64 (1990) 4414-4420
105. Sahli R., Freund R., Dubensky T., Garcea R., Bronson R., and Benjamin T. Defect in entry and altered pathogenicity of a polyoma virus mutant blocked in VP2 myristoylation. Virology 192 (1993) 142-153
106. Streuli C.H., and Griffin B.E. Myristic acid is coupled to a structural protein of polyoma virus and SV40. Nature 326 (1987) 619-622
107. Chow M., Newman J.F., Filman D., Hogle J.M., Rowlands D.J., and Brown F. Myristoylation of picornavirus capsid protein VP4 and its structural significance. Nature 327 (1987) 482-486
108. Tesar M., Jia X.Y., Summers D.F., and Ehrenfeld E. Analysis of a potential myristoylation site in hepatitis A virus capsid protein VP4. Virology 194 (1993) 616-626
109. Moscufo N., Simons J., and Chow M. Myristoylation is important at multiple stages in poliovirus assembly. J Virol 65 (1991) 2372-2380
110. Paul A.V., Schultz A., Pincus S.E., Oroszlan S., and Wimmer E. Capsid protein VP4 of poliovirus is N-myristoylated. Proc Natl Acad Sci USA 84 (1987) 7827-7831
111. Marc D., Drugeon G., Haenni A.L., Girard M., and van der Werf S. Role of myristoylation of poliovirus capsid protein VP4 as determined by site-directed mutagenesis of its N-terminal sequence. EMBO J 8 (1989) 2661-2668
112. Marc D., Masson G., Girard M., and van der Werf S. Lack of myristoylation of poliovirus capsid polypeptide VP0 prevents the formation of virions or results in the assembly of noninfectious virus particles. J Virol 64 (1990) 4099-4107
113. Stack J.H., Herman P.K., Schu P.V., and Emr S.D. A membrane-associated complex containing the Vps15 protein kinase and the Vps34 PI 3-kinase is essential for protein sorting to the yeast lysosome-like vacuole. EMBO J 12 (1993) 2195-2204
114. Babst M., Katzmann D.J., Estepa-Sabal E.J., Meerloo T., and Emr S.D. Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting. Dev Cell 3 (2002) 271-282
115. Hanakam F., Eckerskorn C., Lottspeich F., Muller-Taubenberger A., Schafer W., and Gerish G. The pH-sensitive actin-binding protein hisactophilin of Dictyostelium exists in two isoforms which both are myristoylated and distributed between plasma membrane and cytoplasm. J Biol Chem 270 (1995) 596-602
116. Heuckeroth R.O., Towler D.A., Adams S.P., Glaser L., and Gordon J.I. 11-(Ethylthio)undecanoic acid. A myristic acid analogue of altered hydrophobicity which is functional for peptide N-myristoylation with wheat germ and yeast acyltransferase. J Biol Chem 263 (1988) 2127-2133
117. Wiegand R.C., Carr C., Minnerly J.C., Pauley A.M., Carron C.P., Langner C.A., et al. The Candida albicans myristoyl-CoA:protein N-myristoyltransferase gene. Isolation and expression in Saccharomyces cerevisiae and Escherichia coli. J Biol Chem 267 (1992) 8591-8598
118. Lodge J.K., Johnson R.L., Weinberg R.A., and Gordon J.I. Comparison of myristoyl-CoA:protein N-myristoyltransferases from three pathogenic fungi: Cryptococcus neoformans, Histoplasma capsulatum, and Candida albicans. J Biol Chem 269 (1994) 2996-3009
119. src. Identification of a myristoyl-CoA:glycylpeptide N-myristoyltransferase in rat tissues. Biochem J 250 (1988) 485-491
120. King M.J., and Sharma R.K. Demonstration of multiple forms of bovine brain myristoyl CoA:protein N-myristoyltransferase. Mol Cell Biochem 133 (1992) 77-81
121. Raju R.V., Datla R.S., and Sharma R.K. Overexpression of human N-myristoyltransferase utilizing a T7 polymerase gene expression system. Prot Exp Pur 7 (1996) 431-437
122. Lodge J.K., Jackson-Machelski E., Higgins M., McWherter C.A., Sikorski J.A., Devadas B., et al. Genetic and biochemical studies establish that the fungicidal effect of a fully depeptidized inhibitor of Cryptococcus neoformans myristoyl-CoA:protein N-myristoyltransferase (NMT) is NMT-dependent. J Biol Chem 273 (1998) 12482-12491
123. Ntwasa M., Egerton M., and Gay N.J. Sequence and expression of Drosophila myristoyl-CoA: protein N-myristoyl transferase: evidence for proteolytic processing and membrane localisation. J Cell Sci 110 (1997) 149-156
124. Raju R.V., Kalra J., and Sharma R.K. Purification and properties of bovine spleen N-myristoyl-CoA protein:N-myristoyltransferase. J Biol Chem 269 (1994) 12080-12083
125. Raju R.V., Anderson J.W., Datla R.S., and Sharma R.K. Molecular cloning and biochemical characterization of bovine spleen myristoyl CoA:protein N-myristoyltransferase. Arch Biochem Biophys 348 (1997) 134-142
126. Gunaratne R.S., Sajid M., Ling I.T., Tripathi R., Pachebat J.A., and Holder A.A. Characterization of N-myristoyltransferase from Plasmodium falciparum. Biochem J 348 (2000) 459-463
127. Qi Q., Rajala R.V., Anderson W., Jiang C., Rozwadowski K., Selvaraj G., et al. Molecular cloning, genomic organization, and biochemical characterization of myristoyl-CoA:protein N-myristoyltransferase from Arabidopsis thaliana. J Biol Chem 275 (2000) 9673-9683
128. Dumonceaux T., Rajala R.V., Sharma R., Selvaraj G., and Datla R. Molecular characterization of a gene encoding N-myristoyl transferase (NMT) from Triticum aestivum (bread wheat). Genome 47 (2004) 1036-1042
129. Rundle D.R., Rajala R.V., Alvarez R.A., and Anderson R.E. Myristoyl-CoA:protein N-myristoyltransferases: isoform identification and gene expression in retina. Mol Vis 10 (2004) 177-185
130. Rundle D.R., Rajala R.V., and Anderson R.E. Characterization of Type I and Type II myristoyl-CoA:protein N-myristoyltransferases with the Acyl-CoAs found on heterogeneously acylated retinal proteins. Exp Eye Res 75 (2002) 87-97
131. Selvakumar P, Lakshmikuttyamma A, Sharma RK. Characterization of bovine testis N-myristoyltransferase 2 [in preparation].
132. Rioux V., Beauchamp E., Pedrono F., Daval S., Molle D., Catheline D., et al. Identification and characterization of recombinant and native rat myristoyl-CoA: protein N-myristoyltransferases. Mol Cell Biochem 286 (2006) 161-170
133. Giang D.K., and Cravatt B.F. A second mammalian N-myristoyltransferase. J Biol Chem 273 (1998) 6595-6598
134. Boutin J.A., Clarenc J.P., Ferry G., Ernould A.P., Remond G., Vincent M., et al. N-myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-myristoyl transferase from L1210 microsomes. Eur J Biochem 201 (1991) 257-263
135. Towler D., and Glaser L. Protein fatty acid acylation: enzymatic synthesis of an N-myristoylglycyl peptide. Proc Natl Acad Sci USA 83 (1986) 2812-2816
136. McIlhinney R.A. Characterization and cellular localization of human myristoyl-CoA: protein N-myristoyltransferase. Biochem Soc Trans 23 (1995) 549-553
137. McIlhinney R.A., and McGlone K. Immunocytochemical characterization and subcellular localization of human myristoyl-CoA: protein N-myristoyltransferase in HeLa cells. Exp Cell Res 223 (1996) 348-356
138. Rudnick D.A., McWherter C.A., Adams S.P., Ropson I.J., Duronio R.J., and Gordon J.I. Structural and functional studies of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase produced in Escherichia coli. Evidence for an acyl-enzyme intermediate. J Biol Chem 265 (1990) 13370-13378
139. Rudnick D.A., McWherter C.A., Rocque W.J., Lennon P.J., Getman D.P., and Gordon J.I. Kinetic and structural evidence for a sequential ordered Bi Bi mechanism of catalysis by Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. J Biol Chem 266 (1991) 9732-9739
140. Bhatnagar R.S., Jackson-Machelski E., McWherter C.A., and Gordon J.I. Isothermal titration calorimetric studies of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. Determinants of binding energy and catalytic discrimination among acyl-CoA and peptide ligands. J Biol Chem 269 (1994) 11045-11053
141. Towler D.A., Adams S.P., Eubanks S.R., Towery D.S., Jackson-Machelski E., Glaser L., et al. Purification and characterization of yeast myristoyl CoA:protein N-myristoyltransferase. Proc Natl Acad Sci USA 84 (1987) 2708-2712
142. Duronio R.J., Reed S.I., and Gordon J.I. Mutations of human myristoyl CoA:protein N-myristoyltransferase cause temperature-sensitive myristic acid auxotrophy in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 89 (1992) 4129-4133
143. McIlhinney R.A., Patel P.B., and McGlone K. Characterization of polyhistidine-tagged form of human myristoyl-CoA:protein N-myristoyltransferase produced in Escherichia coli. Eur J Biochem 222 (1994) 137-146
144. Raju R.V., Datla R.S., and Sharma R.K. Expression of human N-myristoyltransferase in Escherichia coli. Comparison with N-myristoyltransferases expressed in different tissues. Mol Cell Biochem 155 (1996) 69-76
145. Glover C.J., and Felsted R.L. Identification and characterization of multiple forms of bovine brain N-myristoyltransferase. J Biol Chem 270 (1995) 23226-23233
146. Towler D.A., Adams S.P., Eubanks S.R., Towery D.S., Jackson-Machelski E., Glaser L., et al. Myristoyl CoA:protein N-myristoyltransferase activities from rat liver and yeast possess overlapping yet distinct peptide substrate specificities. J Biol Chem 263 (1988) 1784-1790
147. Rudnick D.A., Johnson R.L., and Gordon J.I. Studies of the catalytic activities and substrate specificities of Saccharomyces cerevisiae myristoyl-coenzyme A: protein N-myristoyltransferase deletion mutants and human/yeast Nmt chimeras in Escherichia coli and S. cerevisiae. J Biol Chem 267 (1992) 23852-23861
148. McIlhinney R.A., McGlone K., and Willis A.C. Purification and partial sequencing of myristoyl CoA:protein N-myristoyltransferase from bovine brain. Biochem J 290 (1993) 405-410
149. Zhang L., Jackson-Machelski E., and Gordon J.I. Biochemical studies of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase mutants. J Biol Chem 271 (1996) 33131-33140
150. Raju R.V., Datla R.S., Kakkar R., and Sharma R.K. Recombinant bovine spleen myristoyl-CoA:protein N-myristoyltransferase. Mol Cell Biochem 189 (1998) 91-97
151. Bhatnagar R.S., Futterer K., Farazi T.A., Korolev S., Murray C.L., Jackson-Machelski E., et al. Structure of N-myristoyltransferase with bound myristoyl-CoA and peptide substrate analogs. Nat Struct Biol 5 (1998) 1091-1097
152. Glover C.J., Hartman K.D., and Felsted R.L. Human N-myristoyltransferase amino-terminal domain involved in targeting enzyme to the ribosomal subcellular fraction. J Biol Chem 272 (1997) 28680-28689
153. Boutin J.A., Ferry G., Renould A.P., Maes P., Remound G., and Vincent M. Myristoyl CoA:protein N-myristoyltransferase activity in cancer cells. Purification and characterization of a cytosolic isoform from the murine leukaemia cell line L1210. Eur J Biochem 214 (1993) 853-867
154. Pesecks S.M., and Resh M.D. Fatty acyl transfer by human N-myristoyltransferase is dependent upon conserved cysteine and histidine residues. J Biol Chem 269 (1994) 30888-30892
155. McIlhinney R.A., Young K., Egerton M., Camble R., White A., and Soloviev M. Characterization of human and rat brain myristoyl-CoA:protein N-myristoyltransferase: evidence for an alternative splice variant of the enzyme. Biochem J 333 (1998) 491-495
156. Raju R.V., Datla R.S., and Sharma R.K. Genomic organization of human N-myristoyltransferase-1. Biochem Biophys Res Commun 257 (1999) 284-288
157. King M.J., and Sharma R.K. Mechanisms of action of NIP71 on N-myristoyltransferase activity. Mol Cell Biochem 141 (1994) 79-86
158. Magnuson B., Raju R.V., and Sharma R.K. N-Myristoyltransferase activity in rabbit intestine. Biochim Biophys Acta 1300 (1996) 119-124
159. Raju R.V., Kakkar R., Datla R.S., Radhi J.M., and Sharma R.K. Myristoyl-CoA:protein N-myristoyltransferase from bovine cardiac muscle. Molecular cloning, kinetic analysis, and in vitro proteolytic cleavage by m-calpain. Exp Cell Res 241 (1998) 23-35
160. McIlhinney R.A., and McGlone K. A simplified assay for the enzyme responsible for the attachment of myristic acid to the N-terminal glycine residue of proteins, myristoyl-CoA:glycylpeptide N-myristoyltransferase. Biochem J 263 (1989) 387-391
161. Rocque W.J., McWherter C.A., Wood D.C., and Gordon J.I. A comparative analysis of the kinetic mechanism and peptide substrate specificity of human and Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. J Biol Chem 268 (1993) 9964-9971
162. Hatefi Y., and Hanstein W.G. Destabilization of membranes with chaotropic ions. Methods Enzymol 31 (1974) 770-790
163. Nicalau J., and Bacila M. N-Acylsarcosines as inhibitors of respiration and glycolysis and glycolytic enzymes. Arch Biochem Biophys 129 (1969)
164. Rajala R.V., and Sharma R.K. Myristoyl CoA:protein N-myristoyltransferase: subcellular localization, activation and kinetic behavior in the presence of organic solvents. Biochem Biophys Res Commun 208 (1995) 617-623
165. Tomono M., and Kiss Z. Ethanol enhances the stimulatory effects of insulin and insulin like growth factor-1 on DNA synthesis in NIH 3T3 fibroblasts. Biochem Biophys Res Commun 208 (1995) 63-67
166. Parent L.J., Ehrlich R., Marls L., and Singer D.S. Ethanol: an enhancer of major histocompatibility complex antigen expression. FASEB J 1 (1987) 469-473
167. Singh T.J., and Wang J.I.-I. Stimulation of glycogen phosphorylase kinase from rabbit skeletal muscle by organic solvents. J Biol Chem 254 (1979) 8466-8472
168. Raju R.V., Datla R.S., Warrington R.C., and Sharma R.K. Effects of l-histidine and its structural analogues on human N-myristoyltransferase activity and importance of EEVEH amino acid sequence for enzyme activity. Biochemistry 37 (1998) 14928-14936
169. Kolluri S.K., Balduf C., Hofmann M., and Gottlicher M. Novel target genes of the Ah (dioxin) receptor: transcriptional induction of N-myristoyltransferase 2. Cancer Res 61 (2001) 8534-8539
170. Heuckeroth R.O., Glaser L., and Gordon J.I. Heteroatom-substituted fatty acid analogs as substrates for N-myristoyltransferase: an approach for studying both the enzymology and function of protein acylation. Proc Natl Acad Sci USA 85 (1988) 8795-8799
171. lck. Biochemistry 32 (1993) 9250-9255
172. Paige L.A., Zheng G.Q., DeFrees S.A., Cassady J.M., and Geahlen R.L. S-(2-oxopentadecyl)-CoA, a nonhydrolyzable analogue of myristoyl-CoA, is a potent inhibitor of myristoyl-CoA:protein N-myristoyltransferase. J Med Chem 32 (1989) 1665-1667
173. Paige L.A., Zheng G.Q., DeFrees S.A., Cassady J.M., and Geahlen R.L. Metabolic activation of 2-substituted derivatives of myristic acid to form potent inhibitors of myristoyl CoA:protein N-myristoyltransferase. Biochemistry 29 (1990) 10566-10573
174. Towler D.A., Eubanks S.R., Towery D.S., Adams S.P., and Glaser L. Amino-terminal processing of proteins by N-myristoylation. Substrate specificity of N-myristoyltransferase. J Biol Chem 262 (1987) 1030-1036
175. Zheng G.Q., Hu X., Cassady J.M., Paige L.A., and Geahlen R.L. Synthesis of myristoyl CoA analogues and myristoyl peptides as inhibitors of myristoyl CoA:protein N-myristoyltransferase. J Pharm Sci 83 (1994) 233-238
176. Devadas B., Zupec M.E., Freeman S.K., Brown D.L., Nagarajan S., Sikorski J.A., et al. Design and syntheses of potent and selective dipeptide inhibitors of Candida albicans myristoyl-CoA:protein N-myristoyltransferase. J Med Chem 38 (1995) 1837-1840
177. Takamune N., Hamada H., Sugawara H., Misumi S., and Shoji S. Development of an enzyme-linked immunosorbent assay for measurement of activity of myristoyl-coenzyme A:protein N-myristoyltransferase. Anal Biochem 309 (2002) 137-142
178. Georgopapadakou N.H. Antifungals targeted to protein modification: focus on protein N-myristoyltransferase. Expert Opin Investig Drugs 11 (2002) 1117-1125
179. Kawasaki K., Masubuchi M., Morikami K., Sogabe S., Aoyama T., Ebiike H., et al. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Bioorg Med Chem Lett 13 (2003) 87-91
180. King M.J., and Sharma R.K. Identification, purification and characterization of a membrane-associated N-myristoyltransferase inhibitor protein from bovine brain. Biochem J 291 (1993) 635-639
181. Rajala R.V., Dehm S., Bi X., Bonham K., and Sharma R.K. Expression of N-myristoyltransferase inhibitor protein and its relationship to c-Src levels in human colon cancer cell lines. Biochem Biophys Res Commun 273 (2000) 1116-1120
182. Selvakumar P., Lakshmikuttyamma A., Pasha M.K., King M.J., Olson D.J., Mori S., et al. N-myristoyltransferase inhibitor protein is homologous to heat shock cognate protein 70. J Cell Biochem 92 (2004) 573-578
183. Bukau B., and Horwich A.L. The Hsp70 and Hsp60 chaperone machines. Cell 92 (1998) 351-366
184. Bhattacharyya T., Karnezis A.N., Murphy S.P., Hoang T., Freeman B.C., Phillips B., et al. Cloning and subcellular localization of human mitochondrial hsp70. J Biol Chem 270 (1995) 1705-1710
185. Bakkenist C.J., Koreth J., Williams C.S., Hunt N.C., and McGee J.O. Heat shock cognate 70 mutations in sporadic breast carcinoma. Cancer Res 59 (1999) 4219-4221
186. Sturzbecher H.W., Chumakov P., Welch W.J., and Jenkins J.R. Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene 1 (1987) 201-211
187. Blagosklonny M.V., Toretsky J., Bohen S., and Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA 93 (1996) 8379-8383
188. Ehrhart J.C., Duthu A., Ullrich S., Appella E., and May P. Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line. Oncogene 3 (1988) 595-603
189. Zylicz M., King F.W., and Wawrzynow A. Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 20 (2001) 4634-4638
190. Shrivastav A., Pasha M.K., Selvakumar P., Gowda S., Olson D.J., Ross A.R., et al. Potent inhibitor of N-myristoylation: a novel molecular target for cancer. Cancer Res 63 (2003) 7975-7978
191. Ando S., Suzuki M., Yamamoto N., Iida T., and Kimura H. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res 24 (2004) 1941-1946
192. Raju R.V., Datla R.S., and Sharma R.K. Reduction of oncoprotein transformation in vitro by albumin. J Natl Cancer Inst 88 (1996) 556-557
193. Nagase S., Shimamune K., and Shumiya S. Albumin-deficient rat mutant. Science 205 (1979) 590-591
194. Kakizoe T., and Sugimura T. Chemical carcinogenesis in analbuminmic rats. Jpn J Cancer Res 79 (1988) 775-784
195. King M.J., Pugazhenthi S., Khandelwal R.L., and Sharma R.K. Elevated N-myristoyltransferase activity is reversed by sodium orthovanadate in streptozotocin-induced diabetic rat. Biochem Biophys Acta 1165 (1993) 259-262
196. Rothschild M.A., Oratz M., and Schreiber S.S. Albumin synthesis I. N Eng J Med 286 (1997) 748-757
197. Era S., Kuwata K., Imai H., Nakamura K., Hayashi Y., and Sogami M. Age related changes in redox state of human serum albumin. Biochem Biophys Acta 1247 (1995) 12-16
198. c-src in gastric mucosa of aged rats. J Gerontol 49 (1994) B110-B116
199. Gowda S., Shrivastav A., Selvakumar P., Dimmock J.R., and Sharma R.K. A novel inhibitor protein of N-myristoyltransferase from Escherichia coli. Biochem Biophys Res Commun 314 (2004) 984-987
200. Devadas B., Freeman S.K., Zupec M.E., Lu H.F., Nagarajan S.R., Kishore N.S., et al. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoyl CoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity. J Med Chem 40 (1997) 2609-2625
201. Warrington R.C., Fang W.D., and Zhang L.U. l-Histidinol reverses resistance to cisplatinum and other antineoplastics in a tumorigenic epithelial cell line. Anticancer Res 16 (1996) 3641-3646
202. Warrington R.C. Modulation of anticancer drug toxicity by l-histidinol: root for improving human cancer chemotherapy?. Drugs Future 18 (1993) 743-749
203. Dimmock J.R., Jha A., Kumar P., Zello G.A., Quail J.W., Oloo E.O., et al. Cytotoxic 1,4-bis(2-oxo-1-cycloalkylmethylene)benzenes and related compounds. Eur J Med Chem 37 (2002) 35-44
204. Raju R.V., and Sharma R.K. Coenzyme A dependent myristoylation and demyristoylation in the regulation of bovine spleen N-myristoyltransferase. Mol Cell Biochem 158 (1996) 107-113
205. Hansen B.S., Vaughan M.H., and Wang L. Reversible inhibition by histidinol of protein synthesis in human cells at the activation of histidine. J Biol Chem 247 (1972) 3854-3857
206. Warrington R.C., Muzyka T.G., and Fang W.D. Histidinol-mediated improvement in the specificity of 1-beta-d-arabinofuranosylcytosine and 5-fluorouracil in L 1210 leukemia-bearing mice. Cancer Res 44 (1984) 2929-2935
207. Warrington R.C., and Fang W.D. Histidinol-mediated enhancement of the specificity of two anticancer drugs in mice bearing leukemic bone marrow disease. J Natl Cancer Inst 74 (1985) 1071-1077
208. Warrington R.C., Cheng I., and Fang W.D. Effects of l-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in DBA/2J mice. J Natl Cancer Inst 78 (1987) 1177-1183
209. Warrington R.C., and Fang W.D. l-Histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia. Br J Cancer 60 (1989) 652-656
210. Warrington R.C., and Fang W.D. Improved treatment of disseminated B16f10 melanoma in mice with anticancer drugs in combination with l-histidinol. Anticancer Res 11 (1991) 1869-1874
211. Warrington R.C. l-Histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype. Biochem Cell Biol 70 (1992) 365-375
212. Moncada S., Bunting S., Mullane K., Thorogood P., Vane J.R., Raz A., et al. Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins 13 (1977) 611-618
213. Dimmock J.R., Kandepu N.M., Nazarali A.J., Motaganahalli N.L., Kowalchuk T.P., Pugazhenthi U., et al. Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds. J Med Chem 43 (2000) 3933-3940
214. Dimmock J.R., Padmanilayam M.P., Das U., Zello G.A., Sharma R.K., Shrivastav A., et al. Cytotoxic Mannich bases of 1-arylidene-2-tetralones. J Enzyme Inhib Med Chem 18 (2003) 313-324
215. Tsutsui K., Komuro C., Ono K., Nishidai T., Shibamoto Y., Takahashi M., et al. Chemosensitization by buthionine sulfoximine in vivo. Int J Radiat Oncol Biol Phys 12 (1986) 1183-1186
216. Vahrmeijer A.L., van Dierendonck J.H., Schutrups J., van de Velde C.J., and Mulder G.J. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery. Cancer Chemother Pharmacol 44 (1999) 111-116
217. Mitchell J.B., and Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer Suppl 8 (1987) 96-104
218. Brandes L.J., Queen G.M., and LaBella F.S. N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol 45 (2000) 298-304
219. Dimmock J.R., Jha A., Zello G.A., Sharma R.K., Shrivastav A., Selvakumar P., et al. 3,5-Bis(phenylmethylene)-1-(N-arylmaleamoyl)-4-piperidones: a novel group of cytotoxic agents. J Enzyme Inhib Med Chem 18 (2003) 325-332
220. Glover C.J., Tellez M.R., Guziec Jr. F.S., and Felsted R.L. Synthesis and characterization of inhibitors of myristoyl-CoA:protein N-myristoyltransferase. Biochem Pharmacol 41 (1991) 1067-1074
221. Pasha M.K., Selvakumar P., Ashakumary L., Qureshi M., Guziec Jr. F.S., Dimmock J.R., et al. Lipidic inhibitors of human N-myristoyltransferase. Int J Mol Med 13 (2004) 557-563
222. Raju R.V., and Sharma R.K. Demonstration and purification of a myristoyl-CoA binding protein from cardiac muscle. Life Sci 60 (1997) 2145-2153
223. 2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. Science 250 (1990) 979-982
224. Goll D.E., Thompson V.F., Li H., Wei W., and Cong J. The calpain system. Physiol Rev 83 (2003) 731-801
225. Sorimachi H., Ishiura S., and Suzuki K. Structure and physiological function of calpains. Biochem J 328 (1997) 721-732
226. Rogers S., Wells R., and Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 234 (1986) 364-368
227. Saido T.C., Sorimachi H., and Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 8 (1994) 814-822
228. King M.J., and Sharma R.K. Differential activation of bovine brain N-myristoyltransferase(s) by a novel cytosolic activator. Biochem Biophys Res Commun 212 (1995) 580-588
229. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80 (1995) 225-236
230. Rajala R.V., Datla R.S., Carlsen S.A., Anderson D.H., Qi Z., Wang J.H., et al. Phosphorylation of human N-myristoyltransferase by N-myristoylated SRC family tyrosine kinase members. Biochem Biophys Res Commun 288 (2001) 233-239
231. Selvakumar P, Sharma RK. Phosphorylation of human N-myristoyltransferase type 1. Can J Phy Pharm [in press].
232. Arfin S.M., Kendall R.L., Hall L., Weaver L.H., Stewart A.E., and Matthews B.W. Eukaryotic methionine aminopeptidase: two classes of cobalt-dependent enzymes. Proc Natl Acad Sci USA 92 (1995) 7714-7718
233. Pathak V.K., Nielsen P.J., Trachsel H., and Hershey J.W. Structure of the beta subunit of translational initiation factor eIF-2. Cell 54 (1988) 633-639
234. Donahue T.F., Cigan A.M., Pabich E.K., and Valavicius B.C. Mutations at a Zn(II) finger motif in the yeast elF-2 beta gene alter ribosomal start-site selection during the scanning process. Cell 54 (1988) 621-632
235. Brown M.T., and Cooper J.A. Regulation, substrates and functions of src. Biochim Biophys Acta 1287 (1996) 121-149
236. 2-domain for binding is increased during mitosis. J Biol Chem 269 (1994) 10247-10251
237. Magnuson B.A., Raju R.V., Moyana T.N., and Sharma R.K. Increased N-myristoyltransferase activity observed in rat and human colonic tumors. J Natl Cancer Inst 87 (1995) 1630-1635
238. Zhao Y.H., Krueger J.G., and Sudol M. Expression of cellular-yes protein in mammalian tissues. Oncogene 5 (1990) 1629-1635
239. c-src protein tyrosine kinase activity than do differentiated enterocytes. Oncogene 8 (1993) 1033-1039
240. c-src and blockage of its myristoyl acylation with N-fatty acyl compounds resulted in the suppression of colony formation. Biochem Biophys Res Commun 173 (1990) 894-901
241. Johnson D.R., Bhatnagar R.S., Knoll L.J., and Gordon J.I. Genetic and biochemical studies of protein N-myristoylation. Ann Rev Biochem 63 (1994) 869-914
242. Blenis J., and Resh M.D. Subcellular localization specified by protein acylation and phosphorylation. Curr Opin Cell Biol 5 (1993) 984-989
243. Wedegaertner P.B., Wilson P.T., and Bourne H.R. Lipid modifications of trimeric G proteins. J Biol Chem 270 (1995) 503-506
244. c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 84 (1987) 2251-2255
245. Park J., Meisler A.I., and Cartwright C.A. c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene 8 (1993) 2627-2635
246. src myristoylation and membrane association and for cell transformation. Mol Cell Biol 4 (1984) 1834-1842
247. src with Triton X-100-resistant cellular structure correlates with morphological transformation. Proc Natl Acad Sci USA 84 (1987) 2312-2316
248. Toribara N.W., Ho S.B., Bresalier R.S., and Kim Y.S. Biochemical changes in colorectal carcinogenesis. In: Seitz H.K., Simanowski U.A., and Wright N.A. (Eds). Colorectal cancer: from pathogenesis to prevention? (1989), Springer, Berlin 256-288
249. Ward J.M., and Ohshima M. Comparative histogenesis and pathology of naturally occurring and experimentally induced large bowel cancer in the rat. In: Ingall J.R.F., and Mastromarino A.J. (Eds). Carcinoma of the large bowel and its precursors (1985), Alan R. Liss, New York 203-225
250. Haggitt R.C., Glotzbach R.E., Soffer E.E., and Wruble L.D. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 89 (1985) 328-336
251. Galandiuk S., Fazio V.W., Jagelman D.G., Lavery I.C., Weakley F.A., Petras R.E., et al. Villous and tubulovillous adenomas of the colon and rectum. A retrospective review, 1964-1985. Am J Surg 153 (1987) 41-47
252. Harlow S.P., Eriksen B.L., Poggensee L., Chmiel J.S., Scarpelli D.G., Murad T., et al. Prognostic implications of proliferative activity and DNA aneuploidy in Astler-Coller Dukes stage C colonic adenocarcinomas. Cancer Res 51 (1991) 2403-2409
253. Steinberg S.M., Barkin J.S., Kaplan R.S., and Stablein D.M. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 57 (1986) 1866-1870
254. McIlhinney R.A., and McGlone K. Characterisation of a myristoyl CoA:glycylpeptide N-myristoyltransferase activity in rat brain: subcellular and regional distribution. J Neurochem 54 (1990) 110-117
255. c-src activation in human colon carcinoma. J Clin Invest 83 (1989) 2025-2033
256. c-srcin progressive stages of human colorectal cancer. J Clin Invest 91 (1993) 53-60
257. c-src activity in human colorectal metastases. J Surg Res 54 (1993) 293-298
258. c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 87 (1990) 558-562
259. Pena S.V., Melhem M.F., Meisler A.I., and Cartwright C.A. Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology 108 (1995) 117-124
260. c-src in mitosis. Mol Cell Biol 13 (1993) 1464-1470
261. Perpetuo M.D., Valdivieso M., Heilbrun L.K., Nelson R.S., Connor T., and Bodey G.P. Natural history study of gallbladder cancer: a review of 36 years experience at M D Anderson Hospital and Tumor Institute. Cancer 42 (1978) 330-335
262. Raju R.V., Moyana T.N., and Sharma R.K. N-myristoyltransferase overexpression in human colorectal adenocarcinomas. Exp Cell Res 235 (1997) 145-154
263. Selvakumar P., Smith-Windsor E., Bonham K., and Sharma R.K. N-myristoyltransferase 2 expression in human colon cancer: cross-talk between the calpain and caspase system. FEBS Lett 580 (2006) 2021-2026
264. Rajala R.V., Radhi J.M., Kakkar R., Datla R.S., and Sharma R.K. Increased expression of N-myristoyltransferase in gallbladder carcinomas. Cancer 88 (2000) 1992-1999
265. Henson D.E., Albores-Saavedra J., and Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 70 (1992) 1493-1497
266. Wistuba I.I., Miquel J.F., Gazdar A.F., and AlboresSaavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 30 (1999) 21-25
267. Yoshida S., Todoroki T., Ichikawa Y., Hanai S., Suzuki H., Hori M., et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 55 (1995) 2756-2760
268. Hanada K., Itoh M., Fujii K., Tsuchida A., Hirata M., Iwao T., et al. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. Eur J Cancer 33 (1997) 1136-1140
269. Wistuba I.I., Sugio K., Hung J., Kishimoto Y., Virmani A.K., Roa I., et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 55 (1995) 2511-2515
270. Ha M.J., Niklinski W.T., Lee S.J., Miller S.P.F., French S.A., Pirnia F., et al. Protein N-myristoylation as a therapeutic target in hormone refractory prostate cancer. Proc Am Assoc Cancer Res 35 (1994) 24-28
271. Canadian Cancer Statistics, National Cancer Institute of Canada Publication; 2002.
272. Duffner P.K., Horowitz M.E., Krischer J.P., Friedman H.S., Burger P.C., Cohen M.E., et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328 (1993) 1725-1731
273. Canadian Cancer Statistics, Canada; 2003.
274. American Cancer Society. Cancer facts and figures, 2002, Surveillance Research Atlanta, GA 2002. CBTRUS Statistical Report: Primary Brain Tumors in the United States, 1995-1999, 45 Central Brain Tumor Registry of the Unites States, Chicago; 2002.
275. Evans S.M., Judy K.D., Dunphy I., Jenkins W.T., Nelson P.T., Collins R., et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 64 (2004) 1886-1892
276. Wong A.J., Bigner S.H., Bigner D.D., Kinzler K.W., Hamilton S.R., and Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84 (1987) 6899-6903
277. Muleris M., Almeida A., Dutrillaux A.M., Pruchon E., Vega F., Delattre J.Y., et al. Oncogene amplification in human gliomas: a molecular cytogenetic analysis. Oncogene 9 (1994) 2717-2722
278. Sehgal A. Molecular changes during the genesis of human gliomas. Seminar Surg Oncol 14 (1998) 3-12
279. Dehm S.M., and Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 82 (2004) 263-274
280. Warmuth M., Damoiseaux R., Liu Y., Fabbro D., and Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 9 (2003) 2043-2059
281. Russello S.V., and Shore S.K. Src in human carcinogenesis. Front Biosci 8 (2003) s1068-s1073
282. Summy J.M., and Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22 (2003) 337-358
283. Halfter H., Kremerskothen J., Weber J., Hacker-Klom U., Barnekow A., Ringelstein E.B., et al. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor. J Neurooncol 39 (1998) 1-18
284. Hecker T.P., Grammer J.R., Gillespie G.Y., Stewart Jr. J., and Gladson C.L. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res 62 (2002) 2699-2707
285. Marchetti D., Parikh N., Sudol M., and Gallick G.E. Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells. Oncogene 16 (1998) 3253-3260
286. Lu Y., Selvakumar P., Ali K., Shrivastav A., Bajaj G., Resch L., et al. Expression of N-myristoyltransferase in human brain tumors. Neurochem Res 30 (2005) 9-13